Title **Breast cancer assay**

Agency MaHTAS, Health Technology Assessment Section
Medical Development Division, Ministry of Health Malaysia
Level 4, Block E1, Parcel E, Presint 1
Federal Government Administrative Center, 62590 Putrajaya, Malaysia
Tel: +603 88831229, Fax: +603 88831230; htamalaysia@moh.gov.my, www.moh.gov.my

Reference Technology Review Report, 025/2011, online:
http://www.moh.gov.my/technology_reviews/212

Aim

The objective of this technology review was to assess the safety, effectiveness/efficacy and cost-effectiveness of the Breast cancer assay.

Conclusions and results

There was low level evidence available on the efficacy and accuracy of Recurrence Score (RS) by breast cancer assay in assessing the risk of breast cancer recurrence and treatment selection for breast cancer. Consideration should be given to safety issues and the impact of misinterpreted RS results. No evidence was retrieved on the cost-effectiveness of the breast cancer assay.

Methods

Electronic databases searched included PubMed, 2000-2011 EBM Reviews – Cochrane Databases of Systematic Reviews, EBM Reviews - Health Technology Assessment, EBM Reviews – Cochrane Databases of Controlled Trial, Ovid MEDLINE (R), National Horizon Scanning, INAHTA, ASERNIP-S, CADTH and FDA website, for published reports. No search limits were applied. Additional articles were identified from reviewing the bibliographies of retrieved articles

Further research/reviews required

More clinical research and studies should be carried out at our various local clinical settings to ascertain the safety, effectiveness / efficacy and cost effectiveness of the breast cancer assay.

Written by

Maharita AB, MaHTAS, Malaysia